BioMarin Pharmaceutical Inc

BMRN

55.550USD

0.0000.00%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

BioMarin Pharmaceutical Inc's Score

Industry at a Glance

Industry Ranking

26 / 157

Overall Ranking

91 / 4546

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

BioMarin Pharmaceutical Inc Highlights

StrengthsRisks

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 33.15% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.22B.

Fairly Valued

The company’s latest PE is 30.54, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 187.90M shares, increasing 0.04% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 17.35K shares of this stock.

Analyst Rating

Based on 25 analysts

Buy

Current Rating

89.893

Target Price

+66.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of BioMarin Pharmaceutical Inc is 8.25, ranking 63 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 874.57M, representing a year-over-year increase of 17.03%, while its net profit experienced a year-over-year increase of 137.28%.

Score

Industry at a Glance

Previous score

8.25

Change

0



Financials

9.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.45

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.53

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of BioMarin Pharmaceutical Inc is 6.79, ranking 110 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 30.54, which is 764.47% below the recent high of 263.97 and 49.89% above the recent low of 15.30.

Score

Industry at a Glance

Previous score

6.79

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/157

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of BioMarin Pharmaceutical Inc is 8.16, ranking 52 out of 157 in the Pharmaceuticals industry. The average price target is 91.50, with a high of 122.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

8.24

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of BioMarin Pharmaceutical Inc is 6.99, ranking 61 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 61.40 and the support level at 51.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.92

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of BioMarin Pharmaceutical Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 108.82%, representing a quarter-over-quarter decrease of 2.08%. The largest institutional shareholder is The Vanguard, holding a total of 18.07M shares, representing 9.40% of shares outstanding, with 4.76% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

18.49M

-2.22%

BlackRock Institutional Trust Company, N.A.

17.25M

-4.38%

Dodge & Cox

Star Investors

14.69M

-2.79%

PRIMECAP Management Company

Star Investors

15.23M

-3.44%

Norges Bank Investment Management (NBIM)

2.04M

-42.75%

State Street Investment Management (US)

8.76M

-0.94%

AQR Capital Management, LLC

5.93M

+6.30%

Viking Global Investors LP

Star Investors

8.32M

-32.28%

Geode Capital Management, L.L.C.

3.54M

+1.95%

Dimensional Fund Advisors, L.P.

2.25M

+42.68%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioMarin Pharmaceutical Inc is 7.23, ranking 40 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

BioMarin Pharmaceutical Inc

BMRN

7.83 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.73 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment